Navigation Links
Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
Date:2/14/2011

ing body of evidence supporting the drug's antiviral activity in humans.  

Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses.  The Open-Label Study builds on Chimerix's extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs.  CMX001 has been well tolerated in all studies.

CMX001 is also being developed as a medical countermeasure in the event of a smallpox release.  Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases.

Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies.  Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses.  A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.  

<
'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
2. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
3. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
4. Chimerix to Present at Upcoming Investor Conferences
5. Chimerix Initiates Phase 1 Study of CMX157
6. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
7. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
8. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
9. Chimerix Joins International Network of Organizations to Cure Malaria
10. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
11. Cognition Therapeutics Completes $2.5M in Series A1 Financing to Advance Alzheimers Disease Drug Treatment Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... ended March 31, 2015.  Biorem,s complete 2015 first quarter financial statements ... Financial Summary:Three-months ended March 31,(in CDN$,000 except per ... 4,689 , 1,974 Gross profit , 1,531 ... (318) Net earnings (loss) , 528 , (531) ...
(Date:6/1/2015)... , June 1, 2015 ... announced the addition of the "Global PDT ... offering.        (Logo: ... Report 2014 is a professional and in-depth study ... , ,The report provides a basic overview of ...
(Date:6/1/2015)... Regis Technologies, Inc. is a ... stationary phases (CSPs) for analytical and preparative chromatography ... presenting solutions for new clients, Regis implemented a ... addition to its core expertise in chiral chromatography ... tackle projects for the scale clients need–from milligram ...
(Date:6/1/2015)... RESEARCH TRIANGLE PARK, N.C. , June 1, ... FENCF), announced the presentation of positive interim results ... in SIOPEL6: A multi-centre open label randomised phase ... (STS) in reducing ototoxicity in patients receiving cisplatin ... data was presented at the American Society of ...
Breaking Biology Technology:Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3Global PDT Machine Industry Report 2014 2Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4
... Inc., (Nasdaq: MGRM ) announced that it will ... 4:30 p.m. (Eastern Time) to discuss,third quarter 2007 financial ... Young, Chairman and CEO of Monogram. To participate ... 325-4878 for international callers, fifteen minutes before the,conference begins. ...
... Oct. 17 Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) ... 30, 2007. Total revenues in the third quarter ... the third quarter of 2006. Total revenues in the ... $25.9 million in the,first nine months of 2006. Revenues ...
... Diplomat Health Services,in conjunction with McLaren Health Plan, ... Genzyme, announced today the results of its,pilot program ... The,program managed chronic kidney disease patients for McLaren ... savings of $300 per patient per,month compared to ...
Cached Biology Technology:Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call 2Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 2Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 3Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 4Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 5Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 6Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 7Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management 2
(Date:5/22/2015)... May 22, 2015 According to ... Solution (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, Databases), ... and Utilities, Consumer and Home) - Global Forecast to ... from $2.77 Billion in 2015 to $6.19 Billion by ... Browse 79 market data Tables and   43 Figures ...
(Date:5/19/2015)... Fingerprint Cards (FPC) has received an order for ... from one if its module partners. Deliveries are planned to ... the sensors will be used by smartphone manufacturers in ... amount to 740 MSEK to date. In addition to previously ... number of smaller orders not separately communicated amounting to more ...
(Date:5/14/2015)... NEW YORK , May 14, 2015 ... specializing in identity verification and online remote ... Instructure, a software-as-a-service (SaaS) company and creator ... Shared customers of the two companies will ... Proctortrack in Canvas. As a ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... developed in part by DOE,s Oak Ridge National Laboratory ... threats of insects, disease and wildfire. Led by ... computing to incorporate remote sensing data from NASA satellites ... abnormal vegetation patterns and the timing of seasonal changes. ...
... of Understanding signed today, the European Commission (EC) and ... to maintain and further develop their cooperation. , "I ... of Understanding between the European Commission and the European ... set the stage for even better and more fruitful ...
... , This release is available in Spanish ... Linoleico Conjugado y Resvetratrol: efecto de estos ingredientes funcionales sobre ... Linoleic Acid and Resveratrol: the effect of these functional ingredients ... research team member at the University of the Basque Country ...
Cached Biology News:Resveratrol may be useful tool for reducing body fat 2